{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:31:08Z","timestamp":1793853068623,"version":"4.6.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T00:00:00Z","timestamp":1583712000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Shanghai Allist Pharmaceuticals Co., Ltd."},{"name":"China National Major Project for New Drug Innovation","award":["2017ZX09304015"],"award-info":[{"award-number":["2017ZX09304015"]}]},{"name":"China National Major Project for New Drug Innovation","award":["2018ZX09301014009"],"award-info":[{"award-number":["2018ZX09301014009"]}]},{"name":"China National Major Project for New Drug Innovation","award":["2019ZX09201-002"],"award-info":[{"award-number":["2019ZX09201-002"]}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["2016-I2M-1-001"],"award-info":[{"award-number":["2016-I2M-1-001"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.jtho.2020.01.010","type":"journal-article","created":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T03:19:09Z","timestamp":1580354349000},"page":"1015-1026","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":102,"title":["Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation"],"prefix":"10.1016","volume":"15","author":[{"given":"Yuankai","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shucai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingsheng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifeng","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wangjun","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafang","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shukui","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kejing","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2020.01.010_bib1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jtho.2020.01.010_bib2","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1200\/JCO.2015.62.1342","article-title":"Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update","volume":"33","author":"Masters","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2020.01.010_bib3","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.jtho.2016.05.008","article-title":"The International Association for the Study of Lung Cancer consensus statement on optimizing management of EGFR mutation-positive non-small cell lung cancer: status in 2016","volume":"11","author":"Tan","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2020.01.010_bib4","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2020.01.010_bib5","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S1470-2045(13)70355-3","article-title":"Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial","volume":"14","author":"Shi","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2020.01.010_bib6","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1093\/annonc\/mdx359","article-title":"First-line icotinib versus cisplatin\/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung\u00a0adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study","volume":"28","author":"Shi","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2020.01.010_bib7","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","volume":"19","author":"Yu","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2020.01.010_bib8","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMoa044238","article-title":"EGFR mutation and resistance of non-small-cell lung cancer to gefitinib","volume":"352","author":"Kobayashi","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2020.01.010_bib9","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1158\/0008-5472.CAN-18-1281","article-title":"Novel third-generation EGFR tyrosine kinase inhibitors and strategies to overcome therapeutic resistance in lung cancer","volume":"79","author":"Murtuza","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2020.01.010_bib10","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/S1470-2045(19)30504-2","volume":"20","author":"Ahn","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2020.01.010_bib11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12943-018-0778-0","article-title":"Third generation EGFR TKIs: current data and future directions","volume":"17","author":"Tan","year":"2018","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jtho.2020.01.010_bib12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2020.01.010_bib13","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2020.01.010_bib14","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2020.01.010_bib15","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtho.2020.01.010_bib16","unstructured":"ICH- S9. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline; nonclinical evaluation for anticancer pharmaceuticals. 2009."},{"key":"10.1016\/j.jtho.2020.01.010_bib17","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/jnci\/djp079","article-title":"Dose escalation methods in phase I cancer clinical trials","volume":"101","author":"Le Tourneau","year":"2009","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.jtho.2020.01.010_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.jtho.2020.01.010_bib19","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/S1470-2045(16)30508-3","article-title":"Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study","volume":"17","author":"Goss","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2020.01.010_bib20","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","article-title":"AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer","volume":"372","author":"Janne","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2020.01.010_bib21","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.2016.70.3223","article-title":"Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component","volume":"35","author":"Yang","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2020.01.010_bib22","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/annonc\/mdx820","article-title":"CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials","volume":"29","author":"Goss","year":"2018","journal-title":"Ann Oncol"}],"updated-by":[{"DOI":"10.1016\/j.jtho.2020.09.002","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T00:00:00Z","timestamp":1602892800000}}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086420300319?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086420300319?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T19:08:49Z","timestamp":1614625729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086420300319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S1556086420300319"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2020.01.010","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2020.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}